Litigation Details for OTSUKA PHARMACEUTICAL CO., LTD. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2009)

« Back to Dashboard

OTSUKA PHARMACEUTICAL CO., LTD. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2009)

Docket	3:09-cv-05531	Date Filed	2009-10-29
Court	District Court, D. New Jersey	Date Terminated	2013-11-07
Cause	35:271 Patent Infringement	Assigned To	Mary Little Cooper
Jury Demand	None	Referred To	Lois H. Goodman
Parties	OTSUKA PHARMACEUTICAL CO., LTD.
Patents	6,977,257
Attorneys	MELISSA ANNE CHUDEREWICZ
Firms	Patunas Tarantino LLC
Link to Docket	External link to docket

Details for OTSUKA PHARMACEUTICAL CO., LTD. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2009)

Date Filed	Document No.	Description	Snippet	Link To Document
2009-10-29				External link to document

Otsuka v. Teva Abilify Patent Litigation: Case No. 3:09-cv-05531

Last updated: October 26, 2026

Otsuka Pharmaceutical Co., Ltd. sued Teva Pharmaceuticals USA, Inc. in the U.S. District Court for the District of New Jersey over Teva's abbreviated new drug application for generic aripiprazole, marketed by Otsuka as Abilify. The case was part of Otsuka's broader Hatch-Waxman litigation against generic manufacturers.

The dispute centered on U.S. Patent No. 5,006,528, which claimed aripiprazole and was listed for Abilify tablets. Related litigation produced a Federal Circuit decision sustaining the patent's validity and infringement findings against other generic defendants. The Teva action did not produce a separate reported merits opinion comparable to the related Otsuka v. Sandoz decision. Generic aripiprazole entered the U.S. market after expiration of the principal patent and pediatric exclusivity in October 2015.

What was Otsuka v. Teva, 3:09-cv-05531, about?

Otsuka filed the action under the Hatch-Waxman Act after receiving notice of Teva's Paragraph IV certification. Teva sought FDA approval to market generic aripiprazole tablets before expiration of Otsuka's listed patent rights.

The case was:

Field	Detail
Case	Otsuka Pharmaceutical Co., Ltd. v. Teva Pharmaceuticals USA, Inc.
Civil action	3:09-cv-05531
Court	U.S. District Court for the District of New Jersey
Plaintiff	Otsuka Pharmaceutical Co., Ltd.
Defendant	Teva Pharmaceuticals USA, Inc.
Product	Generic aripiprazole tablets
Reference drug	Abilify tablets
Primary patent	U.S. Patent No. 5,006,528
Statutory basis	Hatch-Waxman patent-infringement action under 35 U.S.C. § 271(e)(2)
Regulatory filing	Teva ANDA for aripiprazole
Result	Part of broader generic-aripiprazole litigation; no separately reported Teva merits judgment comparable to the Sandoz appeal

Otsuka alleged that Teva's ANDA product would infringe claims covering aripiprazole. Teva's expected defenses included noninfringement and invalidity, including obviousness.

Which patents protected Abilify aripiprazole tablets?

The central patent was U.S. Patent No. 5,006,528.

U.S. Patent No. 5,006,528

The '528 patent covered aripiprazole, the active pharmaceutical ingredient in Abilify. It was issued to Otsuka and listed in the FDA's Orange Book for Abilify tablets.

The patent had an effective expiration date in April 2015, subject to six months of pediatric exclusivity. The resulting pediatric-exclusivity end date was October 2015. The FDA approved generic aripiprazole products after that protection period ended. [1]

The patent's importance was unusually high because the claims covered the active compound itself rather than only a narrow tablet formulation. A successful validity challenge therefore could have enabled earlier generic entry across multiple ordinary oral solid dosage products.

Formulation and dosage-form patents

Otsuka also held intellectual-property rights relating to Abilify dosage forms and formulations. Those rights did not necessarily prevent approval of every generic aripiprazole tablet after the '528 patent expired.

The principal commercial barrier for standard aripiprazole tablets was the compound patent and its associated pediatric exclusivity. Formulation patents could create separate risks for orally disintegrating tablets, liquid products, or other delivery formats, but they did not automatically extend the blocking period for conventional tablets.

What was Teva's Paragraph IV challenge?

Teva's ANDA included a Paragraph IV certification asserting that the listed Otsuka patent was invalid, unenforceable, or would not be infringed by Teva's proposed product.

A Paragraph IV notice letter creates a statutory cause of action for the brand company. Otsuka's lawsuit triggered the 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), unless the litigation ended earlier or the court issued a decision resolving the patent dispute.

Teva's challenge fit the standard generic strategy:

1. File an ANDA for aripiprazole tablets.
2. Certify against the listed Otsuka patent under Paragraph IV.
3. Require Otsuka to sue within 45 days.
4. Obtain patent litigation protection during the statutory stay.
5. Seek launch after patent expiration, settlement, or a favorable court ruling.

The Paragraph IV case did not by itself establish that Teva could launch before patent expiration. Launch timing depended on the litigation result and any settlement terms.

What did the related Otsuka aripiprazole litigation decide?

The Federal Circuit upheld the validity and infringement findings involving the '528 patent in related litigation against Sandoz and other generic defendants. The appellate court rejected the principal obviousness challenge and affirmed the district court's judgment. Otsuka Pharmaceutical Co. v. Sandoz, Inc., 678 F.3d 1280 (Fed. Cir. 2012).

The Federal Circuit held that a skilled artisan would not have had sufficient reason to select aripiprazole from the relevant prior-art compounds and would not have had a reasonable expectation of success in making the claimed compound. The court also sustained the infringement analysis for the accused generic products.

The related decision strengthened Otsuka's negotiating position in the Teva matter. A final appellate ruling sustaining the compound patent reduced the probability that a generic defendant could win an invalidity trial based on the same obviousness theory.

Why the Sandoz decision mattered to Teva

The Sandoz appeal did not technically decide every issue in the Teva docket. Its commercial effect was broader:

• It confirmed that the '528 patent had survived a substantial obviousness attack.
• It increased the litigation risk for Teva and other generic applicants.
• It supported Otsuka's ability to delay generic entry until patent and pediatric-exclusivity protection ended.
• It reduced the value of an at-risk launch strategy.
• It shifted commercial negotiations toward a licensed or authorized launch date.

Was the Otsuka v. Teva case settled?

The Teva action is generally treated as part of the Abilify generic-entry litigation that concluded without a separately reported trial judgment against Teva. The public litigation record does not contain a Federal Circuit merits decision in the Teva docket equivalent to the 2012 Sandoz opinion.

The available record supports the following assessment:

Issue	Assessment
Separate Teva trial verdict	No widely reported merits verdict
Separate Federal Circuit decision	No reported decision comparable to Otsuka v. Sandoz
Patent outcome controlling commercial entry	Otsuka's '528 patent remained the principal barrier until 2015
Generic launch	Occurred after patent and pediatric-exclusivity protection ended
Settlement economics	Consistent with a delayed-entry or expiration-date resolution, but specific confidential terms are not established in the reported record

Settlement agreements in Hatch-Waxman cases often provide a fixed generic entry date, a license, or an authorized-generic arrangement. Without a public settlement document containing operative terms, the precise Teva launch date, consideration, and restrictions should not be treated as established facts.

When did Abilify lose exclusivity?

Abilify's principal compound-patent protection ended in 2015, with pediatric exclusivity extending the effective protection period into October 2015.

Protection	Date or period	Commercial effect
U.S. Patent No. 5,006,528	April 2015 effective expiration period	Removed the principal compound-patent barrier
Six-month pediatric exclusivity	Through October 2015	Delayed FDA approval of covered generic products
Generic aripiprazole approval and launch	After October 2015	Opened the market to multiple generic manufacturers

FDA approved the first generic aripiprazole tablets in 2015. Teva, Alembic, Aurobindo, Hetero, Torrent, Zydus and other manufacturers participated in the post-exclusivity market. [2]

What was the Orange Book status of Abilify?

The Orange Book listed the '528 patent for Abilify tablets. Orange Book listing made the patent relevant to ANDA applicants and required generic manufacturers to address it through one of four certifications:

• Paragraph I, if no patent information was listed.
• Paragraph II, if the patent had expired.
• Paragraph III, if the applicant accepted approval after patent expiration.
• Paragraph IV, if the applicant alleged invalidity, unenforceability, or noninfringement.

Teva pursued the Paragraph IV route before expiration. The resulting litigation was a conventional patent challenge to the listed compound patent rather than a regulatory dispute over aripiprazole's safety, efficacy, or bioequivalence.

FDA approval of a generic aripiprazole product required satisfaction of the ANDA requirements, including pharmaceutical equivalence, bioequivalence, manufacturing compliance, labeling conformity, and resolution of applicable patent and exclusivity barriers. [3]

How strong was Otsuka's patent estate?

Otsuka's estate was strong for conventional aripiprazole tablets but less uniform across every dosage form.

Strengths

The '528 patent had several advantages:

• It covered the active molecule rather than a narrow manufacturing process.
• It was listed in the Orange Book.
• It generated a statutory stay after Paragraph IV litigation.
• The Federal Circuit sustained its validity in related litigation.
• The patent protected the principal commercial form of Abilify.

Limitations

The estate also had structural limits:

• Patent protection ended in 2015.
• Pediatric exclusivity provided only six additional months.
• Formulation patents could not necessarily block all conventional tablets.
• Generic manufacturers could enter after the compound patent expired.
• Patent protection for oral aripiprazole did not eliminate competition from other antipsychotics.

The estate therefore had high near-term strength and limited long-term duration. Its value was concentrated in the pre-expiration period.

What generic-entry risks existed for Otsuka?

Otsuka faced five principal risks.

Invalidity risk

The primary risk was an obviousness judgment against the '528 patent. The Federal Circuit's decision in related litigation materially reduced that risk.

Noninfringement risk

A generic manufacturer could design its product or labeling to avoid an asserted claim. This risk was lower where the patent claims covered aripiprazole itself.

Section viii carve-out risk

A generic applicant might omit patented indications from its labeling under a section viii statement. That strategy was more relevant to method-of-use patents than to a compound patent covering the active ingredient.

Settlement risk

A settlement could permit generic entry before the full statutory expiration date. The Federal Trade Commission has scrutinized agreements involving delayed generic entry and payments from branded companies to generic applicants. [4]

Post-expiration price erosion

Once multiple ANDA holders entered, aripiprazole pricing and Otsuka's Abilify revenue were exposed to rapid generic substitution. Compound-patent expiry created a broader market event than a single indication-specific patent expiry.

How did Abilify compare with competing antipsychotics?

Abilify's exclusivity profile differed from products protected primarily by method-of-use or formulation patents.

Product	Active ingredient	Principal patent risk	Generic or biosimilar issue
Abilify	Aripiprazole	Compound patent and pediatric exclusivity	Small-molecule ANDA competition
Risperdal	Risperidone	Compound, formulation and method-of-use rights	Small-molecule generic competition
Seroquel XR	Quetiapine fumarate	Extended-release formulation and method-of-use patents	Formulation-specific ANDA risk
Invega	Paliperidone	Compound and extended-release delivery rights	Small-molecule generic competition
Latuda	Lurasidone	Compound and method-of-use patents	Small-molecule ANDA competition
Abilify Maintena	Aripiprazole monohydrate long-acting injection	Injectable formulation, manufacturing and method patents	Generic injectable risk, not biosimilar substitution

Abilify did not face biosimilar competition because aripiprazole is a chemically synthesized small molecule. The relevant pathway was the ANDA process, not the Biologics Price Competition and Innovation Act pathway.

Did biosimilar risk affect this litigation?

No. Biosimilar risk was not relevant to Otsuka v. Teva.

Aripiprazole is a small-molecule active ingredient. Teva's product required an ANDA demonstrating bioequivalence to Abilify. Biosimilar litigation applies to biologic reference products, which are regulated under section 351(k) of the Public Health Service Act.

The commercially relevant risks were generic substitution, patent invalidity, Paragraph IV litigation, formulation design, manufacturing scale-up, and post-entry price erosion.

What manufacturing and intellectual-property barriers remained?

After the '528 patent expired, manufacturers still needed to overcome technical and regulatory barriers:

• Demonstration of bioequivalence.
• Production of consistent tablet strength and dissolution profiles.
• Compliance with current good manufacturing practices.
• Approval of manufacturing sites.
• Stability and batch-release controls.
• Compliance with Abilify-related labeling requirements.
• Management of any remaining formulation or process patents.
• Commercial supply sufficient to support pharmacy substitution.

These barriers could affect launch timing and market share, but they did not recreate the compound-patent exclusivity that ended in 2015.

What was the commercial impact of the Teva litigation?

Abilify was one of Otsuka's largest products before generic entry. Otsuka reported substantial Abilify sales before the loss of exclusivity. The product generated approximately $5 billion in worldwide sales in 2014, according to company reporting. [5]

The litigation protected the product during a high-revenue period. Its commercial value came from delaying generic aripiprazole until the end of the '528 patent term and pediatric exclusivity. Once multiple manufacturers entered, Otsuka faced:

• Rapid reduction in branded prescription volume.
• Generic substitution at the pharmacy level.
• Lower net pricing.
• Reduced value of the conventional tablet franchise.
• Increased importance of newer products and differentiated delivery systems.

The case therefore had greater economic significance than a dispute involving a narrow indication patent.

Key takeaways

1. Otsuka v. Teva, 3:09-cv-05531, was a Hatch-Waxman action over Teva's ANDA for generic aripiprazole tablets.

2. U.S. Patent No. 5,006,528 was the principal patent protecting Abilify's active ingredient.

3. The related Federal Circuit decision in Otsuka v. Sandoz upheld the '528 patent against a major obviousness challenge.

4. The Teva docket did not produce a separately reported merits decision comparable to the Sandoz appeal.

5. Abilify's effective market protection ended in October 2015 after patent expiration and six months of pediatric exclusivity.

6. The litigation involved small-molecule generic risk, not biosimilar risk.

7. Otsuka's strongest protection covered conventional aripiprazole tablets. Formulation and delivery-system patents had narrower commercial reach.

8. Generic entry created major revenue exposure because Abilify had approximately $5 billion in worldwide sales in 2014.

FAQs

Did Teva win the Abilify patent litigation?

There is no separately reported Teva merits victory comparable to the Federal Circuit's decision in the related Sandoz litigation. Generic aripiprazole entered after the principal patent and pediatric exclusivity ended.

What patent number covered Abilify?

U.S. Patent No. 5,006,528 was the principal Orange Book-listed compound patent for Abilify tablets.

Could Teva launch generic aripiprazole before 2015?

An earlier launch would have required a favorable litigation result, a settlement license, or another legally effective resolution. The public record does not establish a separate Teva early-entry judgment.

Was Abilify protected by a biologic patent?

No. Abilify contains aripiprazole, a chemically synthesized small molecule. Generic approval proceeded under the ANDA pathway, not the biosimilar pathway.

Why did the Sandoz decision affect Teva's negotiating position?

The Federal Circuit upheld the '528 patent in related litigation. That ruling reduced the likelihood that Teva could invalidate the same patent through a substantially similar obviousness challenge.

References

1. U.S. Food and Drug Administration. (2015). Approved drug products with therapeutic equivalence evaluations: The Orange Book.
2. U.S. Food and Drug Administration. (2015). FDA approves first generic versions of Abilify.
3. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).
4. Federal Trade Commission. (2013). Agreements filed with the Federal Trade Commission under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.
5. Otsuka Holdings Co., Ltd. (2014). Annual report 2014.
6. Otsuka Pharmaceutical Co. v. Sandoz, Inc., 678 F.3d 1280 (Fed. Cir. 2012).